Dual-target anti-Alzheimer's disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity

J Enzyme Inhib Med Chem. 2019 Dec;34(1):1489-1497. doi: 10.1080/14756366.2019.1634703.

Abstract

MAO-B leads to an increase in the levels of hydrogen peroxide and oxidative free radicals, which contribute to the aetiology of the AD. Thus, both iron ion chelators and MAO-B inhibitors can be used to treat AD. Taking the coumarin derivatives and hydroxypyridinones as the lead compounds, a series of dual-target hybrids were designed and synthesised by Click Chemistry. The compounds were biologically evaluated for their iron ion chelating and MAO-B inhibitory activity. Most of the compounds displayed excellent iron ion chelating activity and moderate to good anti-MAO-B activity. Compounds 27b and 27j exhibited the most potent MAO-B inhibitory activity, with IC50 values of 0.68 and 0.86 μM, respectively. In summary, these dual-target compounds have the potential anti-AD activity.

Keywords: Alzheimer’s disease; MAO-B; coumarin derivatives; hydroxypyridinone; iron ion chelation.

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Coumarins / chemical synthesis
  • Coumarins / chemistry
  • Coumarins / pharmacology*
  • Dose-Response Relationship, Drug
  • Humans
  • Iron Chelating Agents / chemical synthesis
  • Iron Chelating Agents / chemistry
  • Iron Chelating Agents / pharmacology*
  • Molecular Structure
  • Monoamine Oxidase / metabolism*
  • Monoamine Oxidase Inhibitors / chemical synthesis
  • Monoamine Oxidase Inhibitors / chemistry
  • Monoamine Oxidase Inhibitors / pharmacology*
  • Pyridones / chemical synthesis
  • Pyridones / chemistry
  • Pyridones / pharmacology*
  • Structure-Activity Relationship

Substances

  • Coumarins
  • Iron Chelating Agents
  • Monoamine Oxidase Inhibitors
  • Pyridones
  • Monoamine Oxidase

Grants and funding

This project was supported by the National Natural Science Foundation of China, NSFC(Grant No. 21576239 and 81803340).